← Library
Retatrutide
Research Use
Also known as LY3437943
Function
Primary
Obesity · Type 2 Diabetes (investigational)
Mechanism
Triple agonist of GLP-1, GIP and glucagon receptors — combines appetite suppression and insulin sensitization with glucagon-driven energy expenditure.
Evidence
Clinical RCT (Limited)
Research
Phase 3 ongoing; Phase 2 showed up to ~24% weight loss at 48 wk
Dosing
Range
1–12 mg/week (trial doses)
Frequency
Weekly
Route
Subcutaneous
Cycling
Continuous with monthly titration in trials.
Benefits
- ·Largest weight loss seen in GLP-1-class trials
- ·Improved glycemic and lipid profile
- ·Reduced hepatic steatosis
Risks
- ·GI side effects (nausea, vomiting)
- ·Heart rate increase
- ·Unknown long-term safety
Contraindications
- ·MTC / MEN-2 (class)
- ·Pregnancy
- ·Severe gastroparesis
Regulatory
Investigational (Eli Lilly, Phase 3 TRIUMPH program)
Functional Groups
Cited Works
- Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2. N Engl J Med. 2023;389:514.source